Background Denosumab is a monoclonal RANKL antibody, which was originally introduced for the treatment of osteoporosis and bone metastases from solid tumors, but more recently has been used for treatment of giant cell tumor of bone (GCTB). In GCTB, denosumab has been used as a single agent in patients with inoperable tumors; it also has been used before surgery in some patients with the aim to downstage the tumor to facilitate a joint-preserving procedure (curettage) rather than a resection. However, few studies are available evaluating the benefits and risks of denosumab for the latter indication. Questions/purposes (1) Does preoperative treatment with denosumab reduce the risk of local recurrence in patients treated for GCTB? (2) Are there adverse effects of short-term denosumab use before surgery and, if so, what are they?
Methods All patients with a diagnosis of GCTB surgically treated at our institution from June 2009 to June 2016 with curettage and cryotherapy were retrospectively evaluated to compare patients treated with curettage alone versus patients treated with curettage after preoperative therapy with denosumab. During that period, we treated 97 patients for GCTB; 30 patients were excluded because they received a resection; 34 patients were excluded because they received curettage without cryotherapy. Of the remaining 33 patients, four were excluded because they received denosumab only after surgery, one because she received zoledronic acid, one because she received a curettage after her refusal of a resection that was the advised procedure, two because they were lost to followup early, and four because they were treated for recurrence rather than a new diagnosis of GCTB. The remaining 21 patients were included. Twelve lesions had been treated with surgery after denosumab and nine with surgery alone. During the study period, we preferentially used denosumab for the more aggressive-looking lesions. After curettage, cryotherapy of the residual bone walls was performed with argon cryoprobes to -150°C after pouring gel into the cavity, and we then used cement (17 patients) or morcellized allograft (four patients). Tumors were Campanacci Grade 3 in eight of 12 patients in the denosumab group and in two of nine patients in the surgery-only group (p = 0.08), but the extent of epiphyseal juxtaarticular bone involvement was not different between the groups with the numbers available. Median followup was 39 months (range, 14-55 months) in the denosumab group and 27 months (range, 18-92 months) in the surgery-only group. We used chart review to record the proportion of patients in each treatment group who had a local recurrence and to tally adverse events. Results With the numbers available, there was no difference in the proportion of patients experiencing a recurrence (five of 12 in the denosumab group and one of nine in the surgeryonly group; p = 0.18). We found no adverse effects associated with denosumab either during or after treatment; specifically, we found no alterations in electrolyte levels, blood count, or liver and renal function parameters. In this small series, no patient has developed osteonecrosis of the jaw. Conclusions In this small series, use of denosumab before surgery for GCTB appeared to allow the reforming of a bone peripheral rim around the tumor, perhaps facilitating curettage rather than osteoarticular resection in some patients. However, we did not observe a decrease in the risk of local recurrence with the use of denosumab, suggesting that it may not decrease the aggressiveness of the disease; according to our preliminary results, we cannot exclude that the rate of local recurrence could be even higher after curettage in denosumab-treated patients than in nontreated patients, and until or unless larger studies demonstrate such a reduction, primary intralesional surgery without denosumab seems more prudent when curettage is feasible at presentation. We did not observe any adverse effects with denosumab, but we caution readers that this study was underpowered to detect even relatively common complications and relatively large differences in the risk of local recurrence. Future studies should evaluate denosumab prospectively; given the relative rarity of this tumor, we suspect multicenter studies are needed to achieve this. Level of Evidence Level III, therapeutic study.
Introduction
Denosumab, a monoclonal antibody that acts as a receptor inhibitor of nuclear factor-kb ligand (RANKL), originally was used to treat osteoporosis and bone metastases from solid tumors. Because it acts to reduce the formation and survival of osteoclasts, denosumab has more recently been introduced in the treatment of patients with giant cell tumor of bone (GCTB) [4, 21, 22] . Because of its relative novelty, in this setting, denosumab generally is used (1) as the only treatment in patients with locally advanced inoperable tumors or in those with metastatic tumors; (2) as preoperative treatment to facilitate surgery; or (3) in certain patients with large juxtaarticular tumors to make intralesional therapy (like curettage) possible instead of osteoarticular resection [8, 15, 17, 19, 21, 23] .
After the first proposals of the use of denosumab in GCTB [4, 21, 22] , many articles were published addressing the histopathologic effects of denosumab suggesting that denosumab does not kill the neoplastic stromal cells but rather inhibits their activity, forcing them to a quiescent status. By contrast, giant cells, which are not the real tumor cells, disappear and bone regrowth is made possible around and also inside the lesion area [5, 11, 13, 14, 18, 20, 25] . However, few studies are available concerning clinical results of this treatment in terms of recurrence rate [8, 15, 17, 23] , especially when denosumab is used as neoadjuvant therapy before surgical intralesional procedures.
Therefore, we decided to evaluate our series of patients treated with preoperative denosumab and surgical curettage to try to answer the following questions: (1) Does preoperative treatment with denosumab reduce the risk of local recurrence? (2) Are there adverse effects of short-term denosumab use before surgery and, if so, what are they?
Patients and Methods
Between June 2009 and June 2016, we treated 97 patients for GCTB at one institution. For this study, we wished to focus on more aggressive and/or juxtaarticular lesions, which we treated with curettage and cryotherapy and which made up 34% (33 of 97) of the patients with GCTB we treated during that time. Starting in 2012, we began to use denosumab before surgery in patients who we felt were at particularly high risk of recurrence. The current study sought to evaluate the efficacy of that treatment, comparing the group of patients treated only with surgery with the group that received preoperative denosumab.
Because the aim of our study was to evaluate the results in terms of local recurrences of joint-sparing surgery, we excluded 30 patients because they were treated with a resection procedure (24 without preoperative denosumab and six with preoperative denosumab). Thirty-four patients received a curettage, but they were excluded because they did not receive intraoperative cryotherapy. Four more patients were excluded because they had received denosumab only after surgery and one because she had received zoledronic acid. Of the remaining 28 patients, 24 presented with a primary lesion and four with a recurrent lesion. Because we decided to exclude also the patients treated because of recurrent lesions, these four patients also were excluded. Two more patients (both treated only with surgery and cryotherapy) were excluded because they were lost to followup soon after surgery. One more patient (a young woman affected by aggressive GCTB of the distal radius) was excluded because, after denosumab, the CT modifications in tumor characteristics were considered not sufficient to perform a curettage confidently and it was decided that the patient should undergo resection of the distal radius, but the patient refused this kind of surgery and asked for joint-preserving surgery. In this patient, local recurrence was particularly likely to occur because curettage could not guarantee adequate tumor removal and we therefore excluded the patient from the series to avoid bias in the rate of local recurrences.
Twenty-one patients remained for evaluation: 12 patients had surgery after receiving denosumab and nine patients were treated with surgery alone. Cryotherapy was used in juxtaarticular lesions with involvement of subchondral bone when "aggressive" surgical curettage was not possible without damaging the joint or it was considered at high risk for being inadequate; cryotherapy was adopted also in nonjuxtaarticular lesions in case of wide involvement of the bone segment both for its adjuvant effect and to decrease bleeding in locations unfit for tourniquet use such as the pelvis or shoulder girdle. The decision to use denosumab during that period for this indication was generally driven by the extension and aggressiveness of the lesion on the basis of the imaging findings (cortical erosion, soft tissue involvement, subchondral bone involvement). We strongly considered denosumab treatment for patients at definite risk for a resection procedure because of extraosseous expansion of the tumor and only a thin or even interrupted peripheral bone rim around the tumor and patients with a lesion widely involving the subchondral bone, in whom the surgeon was concerned about risks to the joint surface with curettage.
No definite criteria exist to guide between resection and curettage for patients with GCTB. Therefore, an element of subjectivity necessarily remains affecting surgeon choice and the readers must be aware of this when analyzing and comparing the results we present.
In the 97 patients of the whole series, we used denosumab preoperatively in 23 patients; 16 of them received a curettage, one received excision of a soft tissue recurrence, and six received a resection despite denosumab treatment. In the patients who were treated with a resection, the lesions involved the proximal fibula in three patients and the proximal radius, distal femur, and proximal tibia in one patient each.
All the patients were evaluated before surgery with radiographs of the GCTB lesion, MRI with gadolinium, and CT scanning of the lesion and chest. In patients preoperatively treated with denosumab, restaging with local MRI and CT was performed after the end of neoadjuvant therapy, before the surgical procedure. All the tumors were active Stage 2 or aggressive Stage 3 lesions according to the Campanacci classification [7] .
Along with the use of Campanacci grading, with the aim to compare the two groups of patients including different tumoral sites, ranging from the femur to segments as small as a finger phalanx, we decided to evaluate the proportion of epiphyseal bone involvement at presentation, setting as an evaluation parameter the ratio between the maximum diameter of the lesion and the maximum diameter of the epiphyseal bone at the level of subchondral bone or at the level of the lesion most near to the subchondral bone measured on axial two-dimensional CT scan images. For axial or girdle lesions (sacrum, pelvis), the evaluation was conducted similarly, defining as diameter of the involved bone the AP length of the sacral wing and the maximum width of the iliac wing at the involved level. No volumetric evaluation of the tumor was accomplished to analyze tumor size modifications before and after denosumab treatment, because it was not the purpose of the study. According to this parameter, all patients were subdivided into three groups: 76% to 100% involvement, 50% to 75% involvement, or < 50% involvement.
Denosumab treatment was administered at the medical oncology department by a medical oncologist (G. Baldi) according to the following schedule: 120-mg subcutaneous weekly administration for 3 weeks and then 120 mg subcutaneous monthly for 3 months. If the CT evaluation at 3 months showed a peripheral bone rim still inadequate to permit aggressive curettage, the schedule was prolonged for 3 more months to try to obtain a better response. Nine of 12 patients received denosumab also in the adjuvant setting (same dosage of monthly administration for 6 months) as per protocol.
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Intraoperative cryotherapy was administered with cryoprobes reaching -150°C (Endocare Cryocare Systems; HealthTronics, Austin, TX, USA) after filling the void resulting from curettage with a sterile gel. Number and size of the cryoprobes used and number of cycles of freezing (two to three) varied according to size of the lesion and its localization (presence of nearby nerves, vessels, or skin at risk for damage). Filling of the cavity after curettage was performed with cement in most cases (17) or morcellized bone allografts (four).
All the histopathologic specimens were evaluated by an expert pathologist in bone and soft tissue diseases at our pathology department (AF). Radiologic imaging was evaluated by a radiologist (GR) and an orthopaedic surgeon (DAC, GS) dedicated to bone and soft tissue oncology.
After surgery, followup was performed with clinical and local radiographic evaluation after 1 month and then every 3 months for the first year, every 4 months for the second year, every 6 months for the third and fourth years, and annually thereafter. In case of suspicion for local recurrence, an MRI with gadolinium was used for further evaluation. If the suspicion was confirmed by MRI, a CTguided needle biopsy was performed. A chest radiograph was performed once a year.
The patients were followed during denosumab treatment and during followup by a medical oncologist (G. Baldi) and an orthopaedic surgeon (GS, G. Beltrami) dedicated to orthopaedic oncology. During preoperative and postoperative treatment, clinical evaluation was performed by a medical oncologist (G. Baldi) before every administration of denosumab to detect any possible adverse effect in the period between the two administrations. Adverse events and laboratory abnormalities were assessed according to Common Terminology Criteria for Adverse Events (CTCAE; version 3.0), which was in current use at the time of study start. Standard assessments of blood count, liver function, renal function, and electrolytes including calcium were done weekly in the induction phase and then monthly in the maintenance phase. Moreover, every patient underwent at baseline a dental radiograph and a dental visit to exclude risk factors for osteonecrosis of the jaw; then the patients underwent a dental visit every 3 months during treatment.
All patients received daily supplemental doses of calcium and vitamin D.
We used chart review to record the proportion of patients in each treatment group who had a local recurrence and to tally adverse events. In terms of adverse events, we specifically looked for abnormalities in calcium and other electrolytes metabolism or in blood count, liver or renal dysfunction occurrence, osteonecrosis of the jaw, or any other unexpected adverse events observed during denosumab treatment.
At the time of treatment, for each patient receiving denosumab, we requested and obtained authorization by the Regional Therapeutic Commission of Tuscany. At the time of data gathering and evaluation, the study was retrospective and no objection/exception was formulated by the local institutional review board. The study was performed in accordance with the 1975 Declaration of Helsinki.
Statistical Analysis
Differences between groups in terms of clinical and surgical characteristics were assessed using Fisher's exact test. The statistical analysis was performed using R software [16] . A p value of # 0.05 was considered statistically significant.
The median age at presentation was 42 years (range, 17-66 years). The most frequent site of the tumor was the distal femur (seven patients) followed by the distal tibia (four). The other tumors were located in the distal radius and sacrum (two patients at each site) and proximal humerus, distal humerus, finger phalanx, iliac wing, proximal tibia, and patella (one at each site) ( Table 1) .
Median followup was 39 months (range, 14-55 months) in the denosumab group and 27 months (range, 18-92 months) in the surgery-only group.
All of the patients treated with denosumab showed new bone formation around and partially inside the lesion at the radiologic posttreatment evaluation. This allowed us to perform a curettage procedure more confidently. In all nine lesions treated with only surgery, curettage was considered feasible already at presentation.
Tumors in the denosumab group were of a higher grade than in the surgery-only group (Campanacci Grade 3 in eight of 12 patients in the denosumab group and two of nine in the surgery-only group; p = 0.08). However, they were not different in terms of epiphyseal juxtaarticular bone involvement; in terms of this measure, dividing them into those with > 75%, 50% to 75%, and < 50%, the results were eight, four, and zero patients, respectively, in the denosumab group and two, five, and two patients, respectively, in the surgery-only group (p = 0.12).
Results

Local Recurrence
With the numbers available, there was no difference in the proportion of patients experiencing a recurrence (five of 12 in the denosumab group and one of nine in the surgery-only group; p = 0.18; Table 2 ). The recurrences in the denosumab group occurred at a median of 23 months (range, 7-54 months); one of these patients presented three subsequent recurrences and also pulmonary metastases. One patient in the group treated only with surgery and cryotherapy developed a local recurrence at 14 months from surgery. All the recurrences were histopathologically confirmed. The site of the tumor in patients affected by local recurrence was the iliac wing, distal femur, patella (multiple recurrences and pulmonary metastases), proximal tibia, distal tibia, and finger phalanx in one patient each. All six patients underwent revision surgery. Two patients underwent a resection procedure with reconstruction (iliac wing periacetabular region with a custom-made prosthesis; finger phalanx with a composite prosthesis using an autologous bone graft from the iliac crest). Four patients were again treated with curettage. The patient affected by pulmonary metastases was treated with surgery for the local recurrence and was restarted on denosumab, which was recently discontinued, and she is now under strict monitoring.
Adverse Effects
No adverse effect of the use of denosumab was detected either during or after treatment. All the patients completed the treatment schedule without interruption. No alterations in serum levels of calcium or other electrolytes could be found nor did we observe any hematologic or liver and renal function abnormalities. No patient thus far has developed signs of osteonecrosis of the jaw. No malignant neoplastic transformation has been observed in the evaluation of the specimens either from pretreated tumors or from recurrences.
Discussion
The use of denosumab for GCTB in the preoperative setting was greeted with much interest by the orthopaedic community in the hopes of avoiding some osteoarticular resections and complex reconstructive procedures in young patients. Although the use of denosumab in GCTB was introduced almost 10 years ago [22] , few clinical data about its results are yet available [8, 15, 17, 19, 23] . Prior work suggests that denosumab does not eliminate tumor cells but only suppresses their activity [11, 13, 14] . As such, the issue of local recurrence risk seems important, considering that the surgeon operating on a patient with GCTB pretreated with denosumab now faces a different looking tumor than what surgeons have grown accustomed to seeing. Specifically, these denosumab-treated lesions often have a sclerosis in the lesions and a peripheral rim of bone between tumor tissue and remaining healthy bone, which may make it harder for surgeons to appreciate or adjuvant therapies to extend the margins of the curettage. Perhaps because of this, it is possible that the risk of recurrence after treatment with denosumab is greater than patients not thus treated. Although we could not prove this to be the case (because of relatively small numbers and relatively short followup), our data still suggest it may be so, and future studies are needed to confirm this supposition. The major limitation on this study was selection bias. Because this was a retrospective study, randomization was impossible; moreover, because we recently have been treating more aggressive lesions with denosumab, a casecontrol study with contemporaneous controls was not possible. Instead, we tried to identify a suitable control group by limiting the study to patients treated with cryotherapy; these patients' lesions tended to be more aggressive lesions among those we treated. However, as determined by Campanacci grading, selection bias toward the most aggressive tumors being treated with denosumab remained; however, in terms of the extent of epiphyseal involvement, there was no difference between the groups, suggesting the two groups may indeed have been reasonably comparable, at least with respect to that surrogate for aggressiveness. Another limitation was the very small sample size. With the numbers available, we did not see an increased risk of local recurrence in the denosumab group, and we could not demonstrate either a benefit of denosumab on local recurrence control nor an increased risk of recurrence in patients pretreated with denosumab. Nonetheless, the crude incidence of local recurrence in denosumab-treated patients was more than three times higher than in nontreated patients, even if this was not a statistical difference given the small sample size. The low statistical power should cause the reader to interpret our no difference findings cautiously; it is possible that larger studies could demonstrate that indeed there are differences in the risk of local recurrence with or without the use of denosumab that were missed. Likewise, this study is severely underpowered also to detect even relatively common complications and adverse events and therefore we cannot draw any inferences about safety. Even so, we offer the tentative conclusion that denosumab does not prevent local recurrences, which can occur as often or even more often than in nontreated patients. Our purpose in sharing these findings was to share our concerns that the preoperative use of denosumab may be associated with an increased risk of local recurrences of GCTB, even if we could not prove it here. This concern warrants further inquiry by future, larger studies.
The risk of local recurrence we observed after denosumab treatment (41%) is higher than that seen in prior large series of patients with GCTB treated without denosumab but with intralesional surgery and local adjuvants, which have estimated the risk to be between 14% and 19% [2, 9, 10, 12] . We note that those studies included all patients, whereas ours included only the most aggressive lesions, which, as a result of their characteristics, were selected to receive preoperative denosumab. This makes comparing the recurrence risk difficult, and we believe this is important when comparing these results. Two other papers about local control after curettage with preoperative denosumab found a recurrence risk of 15% and 20% [17, 19] , but mean followup in those reports was short, at 13 and 18 months, respectively; we note two of six recurrences in our series occurred > 2 years after surgery (37 and 54 months) and another occurred at 23 months. In terms of the timing of recurrences, our data tentatively suggest that recurrences in patients with giant cell tumors treated with denosumab might occur later than usually observed in historical series [3] and therefore the recurrence rates reported by those other authors could be underestimated.
In our series, local recurrences occurred after denosumab treatment not only in patients who were at presentation particularly at risk for resection surgery (Campanacci Grade 3 lesions with > 75% involvement of the epiphysis at the juxtaarticular level; four of the five recurrences in the denosumab group), but also in one patient with a less aggressive-looking lesion (one of the five recurrences in that group). In fact, it is possible that by using denosumab-which seems to cause sclerosis in the lesions and to create a peripheral rim of bone around them-may make it more difficult for surgeons to appreciate or adjuvant therapies to extend the margins, perhaps making it more likely that local recurrence might occur. We suggest that surgeons pay special attention to aggressive curettage after use of denosumab in patients with GCTB. Even so, the reduction in tumor size caused by denosumab and above all the restoration of a peripheral bone rim around the tumor can make curettage more attractive than resection [19, 23, 24] , which may be a risk worth taking in young patients to preserve function. In this clinical setting, an increased risk of local recurrence can be consciously accepted to try to save the joint and to avoid complex osteoarticular reconstructions in young patients (Fig.  1A-H) .
In our very small series, we did not observe any complications associated with denosumab, but we caution readers that even common complications may not be detected when so few patients are evaluated. Because of that, we can draw no inferences about the safety of denosumab in this setting, and in other series, several adverse effects have been reported [8, 19, 24] , including arthralgia, fatigue, pain in the extremity, headache, nausea, back pain, hypophosphatemia, hypocalcemia, osteonecrosis of the jaw, osteitis, fracture, pneumothorax (in patients affected by pulmonary metastases) and even other neoplasms, myeloproliferative disorders, and malignant transformation of GCTB. Our series used a shorter course of denosumab than some other series [8, 19, 24] , and this could account for the absence of complications in our patients; however, again, we caution readers that the small size of our treatment group also could explain the lack of observed complications. Rekhi et al. [17] , who reported the results of a series of patients treated with a short course of neoadjuvant denosumab, did not report adverse events either, but in their article, this issue was not clearly dealt with. Further monitoring is mandatory, particularly for the reported occurrence of malignant transformation of the tumor after treatment with denosumab [1, 6, 19] .
Although denosumab may decrease the size or extent of these lesions before surgical treatment and may result in the formation of a peripheral rim of bone around the lesions, we remain concerned that it does not decrease the aggressiveness of the disease. The result of this might be that curettage even with adjuvants may not eradicate all of the tumor, and in fact by causing sclerosis in the lesion, it may interfere with the ability of surgeons to appreciate or adjuvant therapies to extend the margins, perhaps increasing the risk of local recurrence. On the basis of this consideration, at present, when the characteristics of a lesion make a curettage procedure feasible at presentation, a primary intralesional surgical procedure without denosumab treatment appears to be the more prudent choice. However, future, larger studies are needed to confirm or refute this premise. In addition, because we have observed some late recurrences among patients pretreated with denosumab, we recommend continued clinical and radiographic surveillance of these patients. . Radiographic (C-D) appearance after 6 months' treatment with denosumab: new bone formation is evident at the periphery and within the lesion. The patient underwent intralesional curettage and cryotherapy was used as a local adjuvant; the intraoperative photographs show the freezing process with three probes inside the cavity filled with sterile gel (E). The bony defect was packed with cement and allogeneic bone grafts in contact with subchondral bone. Plain radiographs at 2-year followup showing no evidence of local recurrence (F). Fifty-four months after primary surgery, coronal MRI shows local recurrence in the distal fibula (G). The patient underwent surgery with cement removal, curettage, and new cementation in both the distal tibia and fibula (H).
